Biopharma · FDA Approvals · Stock
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exc…
Assets on file: denileukin diftitox-cxdl
Dated catalysts for CTOR, including recently decided ones.
Every first-hand event for CTOR, newest first.
Citius Oncology (CTOR) Presents Positive LYMPHIR QoL Data at EORTC-CLTG 2026
Positive quality-of-life (Skindex-29, FACT-G) and pruritus data from the registrational Study 302 of already-approved LYMPHIR were presented at the EORTC-CLTG 2026 meeting; these exploratory results are not in the label.
Companies in the same sector closest to CTOR in market value.